Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Inclusion Criteria: * In good health with no history of major medical conditions. * A total body weight ≥ 50 kg and a BMI of \>18. * Acceptable forms of effective contraception. * An informed consent document signed and dated by the subject and Investigator. * Sero-suitable for Challenge Virus. Exclusion Criteria: * Subjects who have a significant history of any tobacco use at any time (≥ total 10 pack year history, e.g. one pack a day for 10 years). * Subjects who have been pregnant within six months prior to the study, or who have a positive pregnancy test at any point in the study. * Any history or evidence of any clinically significant medical conditions (cardiovascular, gastrointestinal, endocrinological, haematological, hepatic, immunological, metabolic, urological, neurological, psychotic, renal, and/or other major disease or malignancy). * History or evidence of autoimmune disease or known immunodeficiency of any cause. * Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway disease, or chronic lung condition of any aetiology. * Positive human immunodeficiency virus (HIV), Hepatitis A (HAV), B (HBV), or C (HCV) test. * Any significant abnormality altering the anatomy of the nose or nasopharynx. * Any clinically significant history of epistaxis (nose bleeds). * Any nasal or sinus surgery within six months of inoculation. * Recurrent history of clinically significant autonomic dysfunction. * Any abnormal laboratory test or ECG. * Confirmed positive test for drugs of abuse. * Venous access deemed inadequate for the phlebotomy and cannulation. * Any known allergies to the excipients in the Challenge Virus inoculums. * Health care workers who work in units with severely immuno-compromised patients. * Evidence of vaccinations within the four weeks prior to Human Viral Challenge or intention to receive travel vaccination before the last study visit. * Receipt of blood or blood products, or loss (including blood donations) of 450 mL or more of blood, during the 3 months prior to inoculations. * Presence of significant respiratory symptoms existing on the day of challenge or between admission to the unit and inoculation with virus. * History suggestive of respiratory infection within 14 days prior to admission to the unit. * Use within 28 days prior to Human Viral Challenge (Day 0) of nasal steroids \* Use within seven days of any other medication or product (prescription or over-the-counter), for symptoms of hay fever, rhinitis, nasal congestion or respiratory tract infection. * Receipt of systemic: glucocorticoids, antiviral drugs, or immunoglobulins (Igs) or any other cytotoxic or immunosuppressive drug. * Receipt of any systemic chemotherapy agent at any time.